---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-26-104363"
form_type: "8-K"
ticker: "PHGE"
cik: "0001739174"
company_name: "BiomX Inc."
filed_at: "2026-09-29T13:20:17+00:00"
generated_at: "2026-10-12T13:44:16.871346+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Tessera targets 2027 revenue of $14-16M and ~$30M by 2029, implying ~40% CAGR

## Summary
- Initial 2027 revenue target of $14M-$16M, weighted to H2 2026 platform deployments; 2028 target ~$21M and 2029 target ~$30M.
- 2027 target build: $7M from backlog/signed contracts/purchase orders, $5M from existing-customer expansion, $3M from new customers.
- 2027 milestones: 70 platform deployments, 60 new customers, 15 expansion projects, 3 new geographies, 2 new verticals, 16 integrator/channel relationships.
- Targets ~$7-8M (50% of 2027 revenue) from recurring software, licensing, service and support; ~$14M backlog expected by year-end 2027.
- Growth plan combines organic expansion of the Tessera platform (Zorronet, DFSL subsidiaries) with selective future acquisitions; excludes companies under unexercised acquisition options.

## SEC filing metadata
- accession: 0001213900-26-104363
- form_type: 8-K
- ticker: PHGE
- cik: 0001739174
- company_name: BiomX Inc.
- filed_at: 2026-09-29T13:20:17+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1739174/000121390026104363/0001213900-26-104363-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1739174/000121390026104363/ea0306991-8k_tessera.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-26-104363
- JSON: https://secwatch.observer/filing/0001213900-26-104363.json
- Plain text: https://secwatch.observer/filing/0001213900-26-104363.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.